New Commercial Partnership in Greece

Probiotix Health PLC

16 September 2024

 

16 September 2024

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

New Commercial Partnership in Greece

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce a commercial partnership with Greece based consumer brands specialist Eifron SA ("Eifron").

As part of the terms of the agreement, Eifron will introduce YourBiotix_BP tablets, containing LP_LDL®, under its existing probiotic consumer brand, with the anticipated product launch expected to be in Q1 2025. Through this strategic partnership, Eifron will expand its own portfolio by including a product for cholesterol and blood pressure lowering based on LP_LDL®. The addition of other products from the ProBiotix portfolio will be evaluated by the parties on an ongoing basis.  

ProBiotix Health has received a purchase order from Eifron, with the first sales planned for Greece and thereafter in selected regions in Europe.

Founded in 2011, Eifron specialises in innovative healthcare solutions and holds a strong market position, particularly in Greece where it is among the top five brands in the country. Its core focus is addressing unmet medical needs by developing and distributing advanced product solutions for the health sector, with particularly close ties among pharmacies and healthcare professionals. The current Eifron product portfolio includes pharmaceuticals, supplements, and medical devices.

Steen Andersen, CEO of ProBiotix, commented: "This exceptional opportunity to work with a science driven market leader like Eifron represents another significant milestone in our efforts to expand our reach and broaden the availability of our innovative cardiometabolic health product solutions in Europe.

"Eifron's reputation and expertise in the health sector and their commitment to natural solutions makes them an ideal partner for us."

Elias Kartasiadis, CEO of Eifron, added: "We are thrilled to partner with ProBiotix Health and bring their scientifically-backed products to our markets. This partnership aligns perfectly with our mission to provide our customers with effective and natural health solutions.

"We believe this collaboration will help us expand our reach and offer differentiation and added value to the growing group of consumers looking to improve their cardiometabolic health."

For further information, please contact:

ProBiotix Health plc	https://probiotixhealth-ir.com/
Steen Andersen, Chief Executive	Contact via Walbrook below
Peterhouse Capital Limited (Aquis Corporate Adviser and Broker) Mark Anwyl		Tel: [phone]
Walbrook PR Ltd                                                                              Anna Dunphy	[e-mail] Mob: [phone]

 

END